RU2018142605A - Селективный ингибитор фосфатидилинозитол-3-киназы-гамма - Google Patents
Селективный ингибитор фосфатидилинозитол-3-киназы-гамма Download PDFInfo
- Publication number
- RU2018142605A RU2018142605A RU2018142605A RU2018142605A RU2018142605A RU 2018142605 A RU2018142605 A RU 2018142605A RU 2018142605 A RU2018142605 A RU 2018142605A RU 2018142605 A RU2018142605 A RU 2018142605A RU 2018142605 A RU2018142605 A RU 2018142605A
- Authority
- RU
- Russia
- Prior art keywords
- disease
- amount
- gamma
- pi3k
- mediated
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 claims 3
- 101710096503 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Proteins 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 208000003807 Graves Disease Diseases 0.000 claims 2
- 208000015023 Graves' disease Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 206010033647 Pancreatitis acute Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 201000003229 acute pancreatitis Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 206010039083 rhinitis Diseases 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 1
- 108091007960 PI3Ks Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (11)
1. Применение соединения, имеющего следующую структурную формулу:
для лечения опосредованного PI3K-гамма заболевания.
2. Применение по п.1, где опосредованное PI3K-гамма заболевание выбрано из группы, состоящей из астмы, атопического дерматита, ринита, аллергических заболеваний, хронической обструктивной болезни легких (ХОБЛ), септического шока, идиопатического легочного фиброза, инсульта, ожога, заболеваний суставов, ревматоидного артрита, системной красной волчанки, атеросклероза, острого панкреатита, псориаза, воспалительного заболевания кишечника, язвенного колита, болезни Крона и болезни Грейвcа.
3. Фармацевтическая композиция, для лечения опосредованного PI3K-гамма заболевания, содержащая соединение формулы
и фармацевтически приемлемый носитель, адъювант или наполнитель.
4. Композиция по п.3, где опосредованное PI3K-гамма заболевание выбрано из группы, состоящей из астмы, атопического дерматита, ринита, аллергических заболеваний, хронической обструктивной болезни легких (ХОБЛ), септического шока, идиопатического легочного фиброза, инсульта, ожога, заболеваний суставов, ревматоидного артрита, системной красной волчанки, атеросклероза, острого панкреатита, псориаза, воспалительного заболевания кишечника, язвенного колита, болезни Крона и болезни Грейвcа.
5. Композиция по п.3, дополнительно включающая количество по меньшей мере одного терапевтического агента, которое обычно вводят для лечения или предотвращения указанного состояния.
6. Композиция по п.5, где количество указанного по меньшей мере одного терапевтического агента составляет не более чем количество, которое обычно вводят в композицию, содержащую этот терапевтический агент в качестве единственного активного агента.
7. Композиция по п.5, где количество указанного по меньшей мере одного терапевтического агента составляет от примерно 50% до 100% от количества, которое обычно вводится в композиции, содержащей этот агент в качестве единственного терапевтически активного агента.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361882473P | 2013-09-25 | 2013-09-25 | |
| US61/882,473 | 2013-09-25 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016115726A Division RU2675814C2 (ru) | 2013-09-25 | 2014-09-25 | 6,7-ДИГИДРО-5Н-ПИРРОЛО[3,4-b]ПИРИДИН-5-ОН, ПОЛЕЗНЫЙ В КАЧЕСТВЕ СЕЛЕКТИВНОГО ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ-ГАММА |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2018142605A true RU2018142605A (ru) | 2019-02-04 |
Family
ID=51795739
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018142605A RU2018142605A (ru) | 2013-09-25 | 2014-09-25 | Селективный ингибитор фосфатидилинозитол-3-киназы-гамма |
| RU2016115726A RU2675814C2 (ru) | 2013-09-25 | 2014-09-25 | 6,7-ДИГИДРО-5Н-ПИРРОЛО[3,4-b]ПИРИДИН-5-ОН, ПОЛЕЗНЫЙ В КАЧЕСТВЕ СЕЛЕКТИВНОГО ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ-ГАММА |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016115726A RU2675814C2 (ru) | 2013-09-25 | 2014-09-25 | 6,7-ДИГИДРО-5Н-ПИРРОЛО[3,4-b]ПИРИДИН-5-ОН, ПОЛЕЗНЫЙ В КАЧЕСТВЕ СЕЛЕКТИВНОГО ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ-ГАММА |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10301304B2 (ru) |
| EP (2) | EP3049415B1 (ru) |
| JP (1) | JP6340416B2 (ru) |
| KR (1) | KR20160058950A (ru) |
| CN (1) | CN105722838B (ru) |
| AU (1) | AU2014324873B2 (ru) |
| BR (1) | BR112016006388A2 (ru) |
| CA (1) | CA2925601C (ru) |
| CL (1) | CL2016000695A1 (ru) |
| ES (2) | ES2687593T3 (ru) |
| IL (1) | IL244742A0 (ru) |
| MX (1) | MX2016003823A (ru) |
| RU (2) | RU2018142605A (ru) |
| SG (2) | SG11201602265PA (ru) |
| UA (1) | UA117032C2 (ru) |
| WO (1) | WO2015048318A1 (ru) |
| ZA (1) | ZA201702252B (ru) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| ES2900806T3 (es) | 2013-10-04 | 2022-03-18 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos y usos de los mismos |
| SG10201808053XA (en) | 2014-03-19 | 2018-10-30 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| JP6786529B2 (ja) * | 2015-06-29 | 2020-11-18 | バイオメッド バレー ディスカバリーズ，インコーポレイティド | Ｌｐｔ−７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法 |
| JP6980649B2 (ja) | 2015-09-14 | 2021-12-15 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | イソキノリノン誘導体の固体形態、それを製造する方法、それを含む組成物、及びそれを使用する方法 |
| US10858355B2 (en) * | 2016-03-10 | 2020-12-08 | Astrazeneca Ab | Inhibitors of phosphatidylinositol 3-kinase gamma |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CA3134173A1 (en) | 2019-04-10 | 2020-10-15 | Nanjing Zhengxiang Pharmaceuticals Co., Ltd. | Phosphatidylinositol 3-kinase inhibitors |
| US12410170B2 (en) | 2019-06-04 | 2025-09-09 | Arcus Biosciences, Inc. | 2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds |
| US20250333414A1 (en) | 2024-04-30 | 2025-10-30 | Boehringer Ingelheim International Gmbh | Hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament |
| WO2025228902A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Heterocyclic acids as sting antagonists and the use thereof as medicament |
| WO2025228900A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Arylamide substituted indazoles and the use thereof as medicament |
| WO2025228889A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Monoarylic heterocyclic compounds as sting antagonists and the use thereof as medicament |
| WO2025228899A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Further heterocyclic compounds as sting antagonists and the use thereof as medicament |
| WO2025228892A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Monoaryl and hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR071717A1 (es) | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
| UY32582A (es) * | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| SG10201502073PA (en) * | 2009-12-22 | 2015-05-28 | Vertex Pharma | Isoindolinone inhibitors of phosphatidylinositol 3-kinase |
-
2014
- 2014-09-25 RU RU2018142605A patent/RU2018142605A/ru unknown
- 2014-09-25 ES ES14789651.8T patent/ES2687593T3/es active Active
- 2014-09-25 WO PCT/US2014/057499 patent/WO2015048318A1/en not_active Ceased
- 2014-09-25 SG SG11201602265PA patent/SG11201602265PA/en unknown
- 2014-09-25 CA CA2925601A patent/CA2925601C/en active Active
- 2014-09-25 US US15/024,698 patent/US10301304B2/en active Active
- 2014-09-25 AU AU2014324873A patent/AU2014324873B2/en not_active Ceased
- 2014-09-25 SG SG10201802061TA patent/SG10201802061TA/en unknown
- 2014-09-25 BR BR112016006388A patent/BR112016006388A2/pt not_active Application Discontinuation
- 2014-09-25 KR KR1020167010907A patent/KR20160058950A/ko not_active Withdrawn
- 2014-09-25 MX MX2016003823A patent/MX2016003823A/es unknown
- 2014-09-25 EP EP14789651.8A patent/EP3049415B1/en not_active Not-in-force
- 2014-09-25 CN CN201480060785.XA patent/CN105722838B/zh not_active Expired - Fee Related
- 2014-09-25 ES ES18180366T patent/ES2785053T3/es active Active
- 2014-09-25 EP EP18180366.9A patent/EP3412668B1/en active Active
- 2014-09-25 JP JP2016516904A patent/JP6340416B2/ja not_active Expired - Fee Related
- 2014-09-25 UA UAA201604461A patent/UA117032C2/uk unknown
- 2014-09-25 RU RU2016115726A patent/RU2675814C2/ru not_active IP Right Cessation
-
2016
- 2016-03-23 IL IL244742A patent/IL244742A0/en unknown
- 2016-03-24 CL CL2016000695A patent/CL2016000695A1/es unknown
-
2017
- 2017-03-30 ZA ZA2017/02252A patent/ZA201702252B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6340416B2 (ja) | 2018-06-06 |
| RU2675814C2 (ru) | 2018-12-25 |
| HK1223620A1 (zh) | 2017-08-04 |
| MX2016003823A (es) | 2016-08-01 |
| CN105722838A (zh) | 2016-06-29 |
| CN105722838B (zh) | 2017-10-24 |
| EP3049415A1 (en) | 2016-08-03 |
| ES2785053T3 (es) | 2020-10-05 |
| US10301304B2 (en) | 2019-05-28 |
| CA2925601A1 (en) | 2015-04-02 |
| AU2014324873B2 (en) | 2018-11-08 |
| EP3412668A3 (en) | 2018-12-19 |
| KR20160058950A (ko) | 2016-05-25 |
| JP2016531861A (ja) | 2016-10-13 |
| EP3412668B1 (en) | 2020-02-05 |
| SG11201602265PA (en) | 2016-04-28 |
| CL2016000695A1 (es) | 2017-06-09 |
| WO2015048318A1 (en) | 2015-04-02 |
| ES2687593T3 (es) | 2018-10-26 |
| EP3049415B1 (en) | 2018-07-04 |
| BR112016006388A2 (pt) | 2017-08-01 |
| US20160214980A1 (en) | 2016-07-28 |
| EP3412668A2 (en) | 2018-12-12 |
| ZA201702252B (en) | 2019-06-26 |
| SG10201802061TA (en) | 2018-05-30 |
| AU2014324873A1 (en) | 2016-04-21 |
| RU2016115726A (ru) | 2017-10-30 |
| RU2016115726A3 (ru) | 2018-06-20 |
| UA117032C2 (uk) | 2018-06-11 |
| CA2925601C (en) | 2022-11-01 |
| IL244742A0 (en) | 2016-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018142605A (ru) | Селективный ингибитор фосфатидилинозитол-3-киназы-гамма | |
| JP2016531861A5 (ru) | ||
| JP2016540749A5 (ru) | ||
| MX2019006881A (es) | Composicion farmaceutica que comprende derivados de glutarimida y uso de los mismos en el tratamiento de enfermedades eosinofilicas. | |
| WO2014179564A8 (en) | Thiazolopyrrolidine inhibitors of ror-gamma | |
| RU2015139758A (ru) | Хиназолины в качестве ингибиторов киназы | |
| UA95950C2 (en) | 2,6-substituted-4-monosubstituted amino-pyrimidineasprostaglandin d2 receptor antagonists | |
| EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
| TNSN07251A1 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
| JP2016516020A5 (ru) | ||
| JP2017517512A5 (ru) | ||
| HK1212979A1 (zh) | 作為rock抑制劑的酞嗪酮及異喹啉酮 | |
| JP2016509051A5 (ru) | ||
| RU2014136394A (ru) | Морфолиноалкилфумаратные соединения, фармацевтические композиции и способы применения | |
| NZ719185A (en) | Crystalline forms of therapeutic compounds and uses thereof | |
| PH12018500533A1 (en) | Pyrazolyl-substituted heteroaryls and their use as medicaments | |
| JP2016510326A5 (ru) | ||
| JP2017522348A5 (ru) | ||
| JP2016511753A5 (ru) | ||
| JP2016512817A5 (ru) | ||
| EA200900472A1 (ru) | Ингибиторы фосфодиэстеразы iv типа | |
| JP2015526455A5 (ru) | ||
| JP2013507377A5 (ru) | ||
| JP2014521710A5 (ru) | ||
| MX2017015192A (es) | Derivado de bisamida de acido dicarboxilico como agente que estimula regeneracion de tejidos y recuperacion de funcion tisular disminuida. |